Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Mitral valve prolapse syndrome (MVP) is a frequent disorder characterized by a number of complaints which lessen the quality of life.

The pathogenesis of MVP symptoms has not been fully elucidated.

Who Took Part

According to the abstract, 141 subjects were involved.

PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Each person switched between Vitamin D, K2, Magnesium and Zinc and the comparison at some point, usually with a gap in between.

What Was Measured

The researchers assessed serum magnesium in 141 subjects with heavily symptomatic primary MVP and in 40 healthy controls.

The subject headings attached to it are Anxiety, Catecholamines, Echocardiography, Magnesium, Magnesium Deficiency, Mitral Valve Prolapse and Statistics, Nonparametric.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 141 subjects.

The publication is from 1997 (The American journal of cardiology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.